About: Spartalizumab

An Entity of Type: monoclonal antibody, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Spartalizumab (INN; development code PDR001) is a monoclonal antibody and checkpoint inhibitor that is being investigated for melanoma. This drug is being developed by Novartis. As of 2018, spartalizumab is undergoing Phase III trials.

Property Value
dbo:abstract
  • Spartalizumab (INN; development code PDR001) is a monoclonal antibody and checkpoint inhibitor that is being investigated for melanoma. This drug is being developed by Novartis. As of 2018, spartalizumab is undergoing Phase III trials. (en)
dbo:casNumber
  • 1935694-88-4
dbo:fdaUniiCode
  • QOG25L6Z8Z
dbo:kegg
  • D11605
dbo:wikiPageID
  • 58564567 (xsd:integer)
dbo:wikiPageLength
  • 2162 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1036135002 (xsd:integer)
dbo:wikiPageWikiLink
dbp:atcPrefix
  • none (en)
dbp:casNumber
  • 1935694 (xsd:integer)
dbp:kegg
  • D11605 (en)
dbp:mabType
  • mab (en)
dbp:source
  • zu (en)
dbp:synonyms
  • PDR001 (en)
dbp:target
dbp:type
  • mab (en)
dbp:unii
  • QOG25L6Z8Z (en)
dbp:wikiPageUsesTemplate
dcterms:subject
rdf:type
rdfs:comment
  • Spartalizumab (INN; development code PDR001) is a monoclonal antibody and checkpoint inhibitor that is being investigated for melanoma. This drug is being developed by Novartis. As of 2018, spartalizumab is undergoing Phase III trials. (en)
rdfs:label
  • Spartalizumab (en)
owl:sameAs
prov:wasDerivedFrom
foaf:isPrimaryTopicOf
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License